Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein that is required for the survival, growth, and differentiation of hematopoietic progenitor cells. Although the primary structure of GM-CSF is known from cDNA cloning, the relationship between structure and function of GM-CSF is not fully understood. Fifteen different monoclonal antibodies (MoAbs) t o human GM-CSF were generated t o map immunologically distinct areas of the molecule. Each of the MoAbs was biotinylated and shown by enzyme-linked immunosorbent assay t o bind to recombinant GM-CSF that had been affixed t o a solid phase. Each of the 15 unconjugated MoAbs was then used t o compete with each biotinylated MoAb for binding t o GM-CSF. These crossblocking studies identified eight distinct epitopes of native GM-CSF. Seven of these epitopes were also present in denatured GM-CSF by Western blotting, and four of the epitopes were at least partially conserved on GM-CSF that was reduced in P-mercaptoethanol. MoAbs to four of eight RANULOCYTE-MACROPHAGE colony-stimulat-G ing factor (GM-CSF) is a glycoprotein growth factor which induces the proliferation of hematopoietic progenitor cells and functionally activates mature granulocytes and monocyte^.'.^ Both murine and human GM-CSF have been characterized by cloning, sequencing, and functional analysis of recombinant proteins. When the GM-CSF cDNA is expressed in mammalian cells, yeast, or bacteria, the resulting protein products exhibit the expected biologic activities of native human GM-CSF. The processed murine GM-CSF polypeptide (124 amino acids, Mr = 14,346) is 54% homologous to the human GM-CSF polypeptide (127 amino acids, Mr = 14,650); but there is no cross-species activity of these two factors.6
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein that is required for the survival, growth, and differentiation of hematopoietic progenitor cells. Although the primary structure of GM-CSF is known from cDNA cloning, the relationship between structure and function of GM-CSF is not fully understood. Fifteen different monoclonal antibodies (MoAbs) t o human GM-CSF were generated t o map immunologically distinct areas of the molecule. Each of the MoAbs was biotinylated and shown by enzyme-linked immunosorbent assay t o bind to recombinant GM-CSF that had been affixed t o a solid phase. Each of the 15 unconjugated MoAbs was then used t o compete with each biotinylated MoAb for binding t o GM-CSF. These crossblocking studies identified eight distinct epitopes of native GM-CSF. Seven of these epitopes were also present in denatured GM-CSF by Western blotting, and four of the epitopes were at least partially conserved on GM-CSF that was reduced in P-mercaptoethanol. MoAbs to four of eight RANULOCYTE-MACROPHAGE colony-stimulat-G ing factor (GM-CSF) is a glycoprotein growth factor which induces the proliferation of hematopoietic progenitor cells and functionally activates mature granulocytes and monocyte^.'.^ Both murine and human GM-CSF have been characterized by cloning, sequencing, and functional analysis of recombinant proteins. When the GM-CSF cDNA is expressed in mammalian cells, yeast, or bacteria, the resulting protein products exhibit the expected biologic activities of native human GM-CSF. The processed murine GM-CSF polypeptide (124 amino acids, Mr = 14,346) is 54% homologous to the human GM-CSF polypeptide (127 amino acids, Mr = 14,650); but there is no cross-species activity of these two factors. 6 Several different approaches have been taken to define the relationship between the structure and function of GM-CSF.'.'' Studies with synthetic peptides, human/mouse chimeric polypeptides, scanning mutagenesis, and deletional analysis have indicated that there are multiple areas dispersed through the molecule that are obligatory for function. Although these different approaches to identifying the functionally important areas of GM-CSF have not always been in exact agreement, there is a general consensus that 5-10 amino acids at both the amino and carboxy termini are not essential. Residues 14-25 of human GM-CSF were found to be critical for function using chemically synthesized GM-CSF peptides,' and residues 21-31 and 78-94 were required for function using human/mouse hybrid polypeptides (numbering from the first amino acid of the processed 127 amino acid protein as no. 1). 8 For murine GM-CSF, regions 11-15,24-37,47-49, and 81-89 were found to be critical in one mutagenesis study,' and regions 18-22, 34-41, 52-61, and 94-115 in a second mutagenesis study.'" The regions identified in various studies as essential for function may be required either to maintain the structural integrity of the molecule, or could be involved in the epitopes neutralized both recombinant (glycosylated and nonglycosylated) and natural human GM-CSF in a GM colonyforming unit (CFU-GM) assay and blocked GM-CSF-induced activation of neutrophils. For most of the antibodies there was a good correlation between neutralizing activity and the capacity t o block binding of "'I-GM-CSF t o neutrophils or blasts. Non-neutralizing antibodies t o one epitope partially blocked binding of '"I-GM-CSF t o neutrophils. None of the MoAbs neutralized interleukin-3, G-CSF, or M-CSF. The locations of seven of the epitopes could be partially mapped with regard t o the amino acid structure by determining reactivity t o GM-CSF synthetic peptides or t o human-mouse chimeric GM-CSFs. The neutralizing antibodies were found t o map t o amino acids 40-77,78-94, or 110-127. Thus, these MoAbs are useful t o identify functional domains of GM-CSF and in identifying regions that are likely t o be involved in receptor interaction.
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receptor binding site. The introduction of mutations is an excellent method to define essential regions, but does not provide information about the receptor binding sites because changes in function that occur as a consequence of altering even a single amino acid are complicated by the potential problem of also altering secondary or tertiary structure.
In this report we use another approach to the analysis of the functional domains of GM-CSF. Fifteen monoclonal antibodies (MoAbs) have been prepared against recombinant, glycosylated, human GM-CSF. Cross-blocking studies show that eight distinct epitopes have been identified. MoAbs to four of the epitopes neutralized both recombinant (glycosylated and nonglycosylated) and natural GM-CSF, and further blocked binding of Iz5I-GM-CSF to normal neutrophils and acute myeloblastic leukemia (AML) cells. In most cases, the ability of an antibody to block binding of GM-CSF correlated well with its ability to neutralize biologic activity.
Reactivity of several of the antibodies was dependent on the presence of an intact secondary structure of GM-CSF, and thus these antibodies are likely to have complex, nonlinear epitopes. Nonetheless, the locations of seven of eight of the epitopes could b e at least partially mapped in terms of primary amino acid sequence by determining antibody reactivity with either synthetic peptides of GM-CSF or mouseihuman chimeric proteins. These results extend previous studies by better defining both the multiple domains of the GM-CSF molecule that are important for receptor interaction, a n d other domains that are not likely to b e directly involved in ligand binding or receptor activation.
MATERIALS AND METHODS
Reagents. Purified recombinant human GM-CSF (rhGM-CSF) from CHO cells expressing a GM-CSF cDNA was generously provided by Dr Steve Clark, Genetics Institute, Cambridge, MA. Recombinant Escherichia coli-derived human GM-CSF (ScheringPlough/Sandoz, Bloomfield, NJ) and murine GM-CSF (ScheringPlough) were purified to a constant maximal specific activity as described." '*'I-GM-CSF (recombinant CHO-derived GM-CSF) was supplied by Dr Russel Garlick, New England Nuclear-Dupont. Specific activity ranged from 40 to 110 pCi/pg protein with a maximum binding capacity of 80%. The iodinated GM-CSF bad full biologic activity as previously described.'* Bovine serum albumin (BSA, fraction V), ExtrAvidin (a modified avidin) conjugated to alkaline phosphatase, and polyethylene glycol 1500 (PEG) were purchased from Sigma (St Louis, MO). Alkaline phosphataseconjugated goat antimouse Ig and alkaline phosphatase substrates were purchased from Bio-Rad (Rockville Center, NY). Rabbit antimouse Ig was obtained from Dako (Dakopatts; Glastrup, Denmark). Mouse MoAb-isotyping reagents were purchased from Pharmingen (San Diego, CA). Protein A sepharose CL4B was purchased from Pharmacia (Uppsala, Sweden).
Balbic mice were injected intraperitoneal (IP) weekly with 10 pg of glycosylated rbGM-CSF. Following the ninth boost, the mice were bled and serum antibody titer against rhGM-CSF was determined by enzyme-linked immunosorbent assay (ELISA) (below). The animal with the highest titer was given a final intravenous (IV) injection of rhGM-CSF. Three days after the last injection, mice were bled to obtain polyclonal mouse anti-rhGM-CSF, and spleen cells were fused with the NS-1 murine myeloma cell line using PEG. Hybridomas were established by hypoxanthine, aminopterin, thymidine (HAT) selection methods as described previo~sly.~' Hybridomas producing anti-rhGM-CSF were selected by a solid phase ELISA assay. Wells of a 96-well microtiter plate (Bio-Rad) were coated overnight with 0.1 kg/well of rhGM-CSF in 50 mmol/L Tris-buffered saline, pH 8.0 (TBS). Plates were blocked with TBS containing 1% BSA for 30 minutes at room temperature. After addition of supernatants, plates were washed with TBS containing 0.05% Tween 20 (TBST) and incubated with alkaline phosphatase-conjugated goat antimouse Ig. After an additional 1 hour, plates were washed and incubated with alkaline phosphatase substrate solution. The plates were read with an ELISA reader at 405 nm. Positive hybridomas were selected and recloned by limiting dilution, grown in ascites fluid, and the antibodies were purified by ammonium sulfate precipitation. The affinity constant of each antibody was estimated as previously describedI4 using the formula K = l/C,,,,where CtS, is the concentration of antibody required for 50% of maximal binding. The isotype of each antibody was determined by an ELISA assay using rat antimouse MoAb isotyping reagents according to the manufacturer's instructions.
Supernatants of positive Production of MoAbs.
Immunoprecipitation of "'I-GM-CSF. 8 .0,150 mmol/L NaCI) containing 1% gelatin (Bio-Rad) for 1 hour at 25°C. The blots were then washed in TBST and incubated overnight with each supenatant or purified antibody (2 pg/mL). The primary antibody was removed and the blots were washed in TBST. To detect antibody binding, the blots were incubated 2 hours with alkaline phosphataseconjugated antimouse Ig, washed three times in TBST, and developed in a buffer containing 100 mmol/L Tris-HCI, pH 9.5,100 mmol/L NaCI, 5 mmol/L MgCl,, 330 mg of Nitro blue tetrazolium (NBT) per milliliter, and 150 mg of 5-bromo-4 chloro-3-indolyl phosphate (BCIP) as previously de~cribed.'~ To determine the number of distinct epitopes and the relationship of the epitopes identified by each of the antibodies, cross-blocking studies were performed. Each of the purified antibodies was conjugated to biotin according to the methods of Bayer et a1.I6 Each biotinylated antibody (0.8 kg/mL) was mixed with onefold to 625-fold excess of unconjugated MoAbs, and the mixtures were added to rhGM-CSFcoated wells. Binding of each biotinylated antibody to rhGM-CSF was quantitated using an ELISA assay (above) developed with alkaline phosphatase-extravidin.
The ability of each MoAb to neutralize rhGM-CSF was investigated using a colony assay for normal marrow progenitor cells. Each purified MoAb was incubated with rhGM-CSF (final concentration: 6.25 ng/mL) or MO cell conditioned medium" for 1 hour at room temperature and residual GM-CSF activity was measured in a GM colony-forming unit (CFU-GM) assay as previously described." Briefly, bone marrow mononuclear cells (105/mL) were cultured in 0.3% agar containing the mixture of rhGM-CSF and MoAb. Normal bone marrow cells were obtained from volunteers who gave informed consent approved by the institutional review board. CFU-GM in quadriplicate cultures were counted on day 7. In addition to CFU-GM assay, MTT (3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide; Sigma) incorporation was used to measure proliferation of the factor-dependent M07E cell line.'' Triplicate aliquots of M07E cells" were cultured in flat bottom microtiter plates (100 p,L/well) for 72 hours at 37°C. MTT was added for the final 4 hours of culture (10 JLL of 5 mg/mL solution of MTT in PBS). At 72 hours, 100 pL of acid isopropanol (0.04 N HCI in isopropanol) was added to all wells, mixed, and the optimal density measured on an ELISA reader at 560 nm.
The effects of anti-GM-CSF antibodies in neutralizing rhGM-CSF-induced activation of neutrophils was also evaluated. GM-CSF has been shown to rapidly induce surface expression of a granulocyte adhesion molecule (CDllb, Mol) in vitro2" and in vivo." The effect of MoAbs on the CDllb upregulation was quantitated by flow cytometry as previously described.*' Briefly, normal peripheral blood was collected into heparinized plastic syringes and placed immediately at 4°C in polystyrene test tubes.
Immunoblotting.
Epitope determination by cross-blocking studies.
Assays for biologic activity.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From One hundred microliters of whole blood was incubated for 30 minutes at 37°C with rhGM-CSF (final concentration: 5 ng/mL) pretreated with each MoAb for 1 hour at room temperature. After washing with PBS, whole blood was incubated at 4°C with MoAb antibody 904 (anti-CDllb) for 30 minutes; this was followed by two washes in PBS. The cells were then further incubated with fluorescein conjugated-antimouse Ig (Tago, Burlingame, CA) for 30 minutes at 4°C followed by two additional washes in PBS. Lysis of erythrocytes was then accomplished using the Coulter whole blood lysis reagents (Coulter Immunology, Hialeah, FL). The leukocytes were then fixed by in formaldehyde-methanol fixative and subsequently analyzed by flow cytometry in a Coulter EPICS-C flow cytometer. Granulocyte "windows" were set on the basis of 90" light scatter, and only this fraction was analyzed for surface fluorescence.
Cells, 5 x lo6, were suspended in 300 pL of binding buffer (BB) consisting of RPMI 1640 (GIBCO, Grand Island, W ) with BSA (2 mg/mL) and 25 mmollL HEPES. Varying amounts of iodinated GM-CSF were added in the presence or absence of an approximately 100-fold excess of cold ligand to assess specifically bound counts, with a final incubation volume of 500 )LL in 1.5 mL polypropylene tubes (Sarstedt Inc, Princeton, NJ). Equilibrium conditions were determined to occur after 1.5
hours of binding at 37°C in the presence of sodium azide (0.02% wthrol) and were used for analysis. Under these conditions, nonspecific binding was typically in the range of 5% to lo%.'* After incubation, the cells were resuspended, layered over a cushion of 0.75 mL of 75% fetal calf serum (FCS), and spun for 30 seconds in a microfuge. After aspirating the supernatant, the cell pellets were cut off and counted with an efficiency of approximately 70% (LKB Gammamaster 1277, Washington, DC).
Peptides were synthesized using a solid phase method as described,= using t-butyloxycarbonyl amino protecting group, symmetrical anhydrides, and an Applied Biosystems model 430A peptide synthesizer, based on the sequence as des~ribed.",~ Following removal of protecting groups, the peptides were cleaved from the resin with hydrogen fluoride. Crude peptides recovered from the resin were analyzed by reverse-phase high performance liquid chromatography (HPLC) on a Rainin Dynamax C-8 column (12-m particle size, 300-A pore size, 4.6 mm X 250 mm; Rainin, Inc, Woburn, MA). Antibody reactivity with peptides was determined by ELISA as above except the wells were coated with 0.5 pghell peptide, and the second stage antibody was horseradish peroxidase-conjugated goat antimouse IgG + IgM (1:5,OOO, Jackson Labs 111-035-068, Westgrove, PA). The plate was developed at 1 hour with either 2,2'-azino-bis-(3-ethyl-benzthiazoline sulfonate) or 3,3', 5,5'-tetramethylbenzidine and hydrogen peroxide. In the case of antibody 3034, the second stage antibody was goat antimouse IgA (1:10,000, Cappel Labs no. 3211-0021, Malvern, PA).
Human-mouse hybrid GM-CSF cDNA expression vectors (hm 3,6,9, 10, and 19) were produced as previously described? COS cells transfected with human-mouse hybrid cDNA expression vectors were grown as previously for 24 hours, washed, and switched to labeling medium (Dulbecco's modified Eagle's medium devoid of methionine or cysteine with 1% dialyzed FCS and 40 pCi/mL I5S-methionine or "S-cysteine). After 2 days, supernatants were collected and aliquots were precleared by incubation with 1/10 vol Staphylococcus aureus at 4°C. Following centrifugation, the supernatants were incubated with either rabbit anti-GM-CSF polyvalent antisera 1:160, 3 pg/mL of each murine MoAb at 4°C for 4 to 5 hours. Samples containing the MoAbs were additionally incubated with 6 pg/mL rabbit-antimouse IgG at 4°C for 90 minutes. Immune complexes were then precipitated by Receptor binding assay.
Synthetic GM-CSF peptides.
Human-mouse hybrid GM-CSF and immunoprecipitation.
incubation with S aureus 10 voVpg of antibody. Following centrifugation, pellets were resuspended in reducing dye, boiled, and loaded onto 12% SDS-polyacrylamide gels for electropheresis. The gels were treated with Enlightening reagent (NEN Research Products, Boston, MA), dried and exposed to film for 2 to 14 days.
RESULTS
Characteristics of anti-GM-CSF MoAbs. MoAbs were selected by their ability to react with recombinant GM-CSF afbied to a solid phase, using an ELISA assay. Table 1 shows the results from a typical experiment with hybridoma culture medium supernate (results with ascites fluid were similar). The reactivity of these antibodies with GM-CSF was further evaluated by testing their ability to immunoprecipitate iodinated recombinant, glycosolated GM-CSF from solution ( Table 1 Figure 1 shows the cross-blocking study of one antibody representative of each of the eight epitopes. Seven antibodies reacted with the same epitope, represented by prototype antibody 1022 in Fig 1 (antibodies 1009,1011,1028,2009 ,2077,2101, and 3135). Two antibodies reacted with the 3092 epitope, and the other antibodies reacted with unique epitopes.
The ability of each MoAb to neutralize the proliferation-inducing activity of recombinant GM-CSF was investigated using a standard marrow CFU-GM assay (Fig 2) unbound GM-CSF, and counted.
tained using three different concentrations of natural GM-CSF (0.1%, 1%, and 10% MO cell conditioned medium) to stimulate CFU-GM growth (data not shown). Also, similar results were obtained using a short-term proliferation assay (72 hours) with the factor-dependent human M07E cell line with a higher concentration of recombinant GM-CSF (10 ng/mL). In other data not shown, the neutralizing antibodies were shown to neutralize natural and E coliderived GM-CSF, suggesting that the neutralizing activities of these antibodies are not dependent on a carbohydrate epitope. The effects of selected antibodies in neutralizing recombinant CHO-derived human GM-CSF-induced activation of neutrophils was also evaluated. One of the most rapid effects of GM-CSF on the neutrophil is upregulation of CDllb. CDllb upregulation was quantitated by flow cytometry 30 minutes after adding GM-CSF, pretreated with or without various MoAbs. Control isotype-matched antibody 3CllC8 (anti?-interferon) had no effect on the dosedependent upregulation of CDllb (Fig 3) . Except for antibody 21 18, each of the antibodies that neutralized GM-CSF-induced proliferation of CFU-GM or M07E cells also neutralized GM-CSF-induced neutrophil CDllb upregulation, in approximately the same rank order (Fig 3  shows data for representative antibodies) . Antibody 21 18 did not neutralize GM-CSF-induced upregulation of CDllb, but previously had been found to have the highest IC,, of any of the neutralizing MoAbs (Fig 2) . Thus, the relative neutralizing abilities of the different antibodies remained very similar in repeated experiments in both assay systems and over a broad range of CSF concentrations, with the possible exception that 2118 was more effective at neutralizing the effects of GM-CSF on CFU-GM than on neutrophils.
The neutralizing antibodies are shown as dotted lines in Fig 1, and the non-neutralizing antibodies as solid lines. Antibody 2118 is shown as a neutralizing antibody because of its effects on CFU-GM proliferation. The cross blocking studies suggest that the relationships between the neutralizing and the non-neutralizing epitopes is complex. For example, the non-neutralizing antibody 1022 effectively competes for binding with the weakly neutralizing antibody 2118, partially competes for binding with the strongly neutralizing antibody 3034, and has no effect on the binding of neutralizing antibodies 1089 or 3092. Conversely, while 2118 competes for binding of 1022, it blocks binding of 3092, but not 3034.
The ability of the antibodies to inhibit binding of '"1-GM-CSF to the GM-CSF receptor was evaluated in a competitive binding assay. Neutrophils from three separate donors were studied, as were blasts from a single case of Ah4L that were shown in other experiments to respond to GM-CSF in agar culture (Fig 4) . The 1251-GM-CSF used in these studies was shown to have full biologic activity in a proliferation assay using MO7E cells when compared with non-iodinated GM-CSF. A single, high concentration of MoAbs (10 pg/mL) was used to block binding of a single, saturating concentration of lZ5I-GM-CSF (approximately 10 ng/mL). Preliminary studies indicated that 10 pg/mL of each antibody was sufficient to produce maximum inhibition. For most antibodies there was excellent correlation between
Inhibition of GM-CSF receptor binding.
For the ability to neutralize GM-CSF biologic activity on early hematopoietic cells (CFU-GM and M07E cell line) and the ability of the antibody to block binding of GM-CSF to the GM-CSF receptor expressed on neutrophils. For example, antibody 3092 could completely neutralize biologic activity and block binding of GM-CSF at 10 kg/mL and antibody 1022 neither neutralized nor blocked. However, two antibodies gave unanticipated results. Antibody 1089 was consistently more effective at neutralizing biologic activity of GM-CSF on CFU-GM, compared with blocking of binding of GM-CSF to neutrophils or blasts (compare Figs 2,3, and 4) . The apparent inability of antibody 1089 to block binding of lzI-GM-CSF to neutrophils may be an artifact due to binding of 'zI-GM-CSF/antibody complexes to Fc receptors. At high antibody concentrations, the nonspecific binding increased substantially, from less than 5% to greater than 50%, even though the experiments were performed in the presence of both 10% human AB serum and 10 pg/mL of an irrelevant isotype-matched control antibody (3CllC8, an IgG, anti-y-interferon MoAb).25 This presumed Fc binding is difficult to explain because all of the antibodies, except 3034, are of the same isotype (IgG,). Antibody 2118, in contrast, was reproducibly as effective as 3092 in blocking binding of GM-CSF to neutrophils and to AML blasts, but was the least active in neutralization studies, particularly in neutrophils (compare Figs 3 and 4) .
1022; (-O-), 1043; (--O--), 1089; (-W-),

2114; (--A--), 2118; (--A--), 3034; (--0--), 3092; (---),
4117.
The identification of epitopes in terms of linear amino acid sequence (primary structure) is complicated by the fact that some epitopes involve two or more areas that may be distantly separated in the primary structure, but are brought together by folding of the molecule. Also, some or all of an epitope may involve
Epitope mapping.
For recombinant GM-CSF expressed in a mammalian cell line was evaluated by immunoblotting. SDS-PAGE would be expected to eliminate tertiatry structure. Murine heteroantiserum to rhGM-CSF identified three broad bands in our preparation of human GM-CSF, over an apparent molecular weight range of 15,000 to 30,000 daltons (pre-immune serum did not identify any bands 
Abbreviation: ND, not determined. 'Peptides were synthesized as described in Materials and Methods, and affixed to microtiter wells. Antibody binding to peptides was determined by ELISA. Any changes in amino acid sequence from authentic GM-CSF are shown in parentheses.
reactivity, while antibody 4117 had full reactivity with reduced GM-CSF. These results suggested that the antibodies whose epitopes were most likely to be linear, and, therefore, most easily mapped using short GM-CSF synthetic peptides, were 1022, 3034, 3092, and 4117. Preliminary studies showed that these antibodies did, in fact, bind to selected GM-CSF peptides, and, therefore, more extensive epitope mapping studies were performed.
A series of peptides that overlap the entire GM-CSF molecule were synthesized, and reactivity of selected antibodies was measured by ELISA ( Table 2) . As a control, two antibodies that failed to react with reduced GM-CSF (1089 and 1001) were analyzed on the entire series of peptides and were found not to react with any peptides tested, further suggesting that these epitopes are not linear. Non-neutralizing antibody 41 17 reacted with a peptide containing the first 16 amino acids of the processed GM-CSF (residues 1-16), but not with a peptide containing 6-25 (CYS), suggesting that the epitope involves at least the first five amino acids of processed GM-CSF, AF'ARS. Interestingly, the antibody does not recognize murine GM-CSF, where the first five amino acids differ only at position 3, AF'TRS, suggesting that residue 3 may be part of the epitope.
Two antibodies, 1022 (non-neutralizing) and 3034 (neutralizing) recognized peptides 110-127, 102-127, and 88(SER)-127, but not peptides 89-101, 94-119, or 96-111, suggesting that a portion of these epitopes may lie within 120-127, or at least within 110-127. The reactivity of antibodies 1022 and 3034 with mercaptoethanol-reduced GM-CSF was attenuated, further suggesting that part of these epitopes could involve cysteine-121.
These results are consistent with, and help explain, the cross-blocking studies. 1022 partially blocks binding of 3034, and 3034 completely blocks binding of 1022 (Fig l) , while 4117 has no effect on the binding of 1022 or 3034, or vice versa. These results further suggest that the epitopes of several other antibodies are "near" (at least in tertiary structure) 110-127, including 2114 (closer to 1022 than 3034) and 2118 (close to 1022, but not to 3034). Similarly, the epitopes for non-neutralizing antibody 1043 and neutralizing antibodies 1089 and 3092 may not be close to 110-127.
To further define the functional epitopes of GM-CSF, selected MoAbs were tested for their ability to immunoprecipitate a series of hybrid murine/human GM-CSF molecules previously des~ribed.8,~~ In preliminary experiments, the antibodies were shown not to bind to or neutralize murine GM-CSF, as anticipated from the fact that they are murine antibodies. Thus, any reactivity observed with the hybrid molecules would be because of binding to the human segments. The results in Table 3 can be used to estimate the shortest segment of GM-CSF that is likely to contain at least part of the epitope of each antibody. Thus, the epitope of antibody 1022 is likely to contain residues 78-94, because the antibody reacts with hm 19, but not hm 6. Similarly, the minimal epitopes for other antibodies identified by this technique were 40-77 (1089), 78-94 (2114), 78-94 (2118),  78-94 (3034), 78-94 (3092), and 1-22 (4117) . However, it is 
when the epitope is near the end of a human segment, and, thus, these results must be interpreted cautiously and in the context of other available information. The epitopes of 1022 and 3034 may be particularly complex. Using synthetic peptides, both epitopes map to the carboxy terminus, 110-127. However, both antibodies immunoprecipitate some hm 19, containing human segment 20-94. The antibodies do not react with peptides spanning this region, with the exception of 88(SER)-127. A peptide from 89-101 was negative. One or both of these antibodies may have discontinuous epitopes, or, alternatively, may react with some mouse sequence if another critical part of the epitope is present from human GM-CSF. Overall, the humadmouse hybrid data confirm and extend the results obtained with synthetic GM-CSF peptides and cross-blocking. The best estimate of epitope mapping combining the results with both hybrid molecules and peptides, is presented in Table 4 and Fig 5. Table 4 also summarizes the results from cross-blocking studies, which are an estimate of the "closeness" of epitopes in tertiary structure, and compares the current series of antibodies with two previously published anti-GM-CSF MoAbs."
DISCUSSION
We report the generation of a series of MoAbs that recognize at least eight different epitopes expressed on human GM-CSF. Antibodies to four of the epitopes block GM-CSF receptor binding and activation to a variable degree, and these epitopes may be in, or near, the "receptor binding site" of GM-CSF. Four other epitopes were identified that are clearly not important for ligand-receptor interaction, because even concentrations of antibody in excess of 25 pg/mL neither blocked binding of GM-CSF nor prevented receptor activation.
The identification of the regions of GM-CSF that are critical for function is important for several reasons. This information may be useful in designing synthetic molecules that are more potent than the natural compound. Altematively, it may be possible to design a synthetic GM-CSF that binds to the receptor, but does not activate it, thus blocking the receptor. Blocking the receptor could be useful in inflammatory disorders or in certain neoplasms where GM-CSF may be a growth factor, such as AML. Further, anti-idiotypic antibodies could be useful as probes for GM-CSF receptors.
Several approaches have been taken to identify critical regions of GM-CSF. Clark-Lewis et a1 produced synthetic human GM-CSF peptides, and showed that residues 1-13 (where no. 1 is the N-terminal amino acid of the mature 127 aa protein) and 122-127 were not required for activity.' A peptide consisting of residues 31-96 had low, but detectable For personal use only. on October 24, 2017. by guest www.bloodjournal.org From activity. Synthetic peptides within 1-53 completely lacked biologic function. However, the integrity of residues 14-42, particularly residues 16-18, were shown to be critical for biologic activity, and a synthetic peptide of residues 31-113 was biologically active. ' One of the most informative approaches has taken advantage of the fact that human and mouse GM-CSFs are species-specific, and a series of mouse/human hybrid cDNAs has been generated? By determining which hybrid molecules are biologically active in each species, two regions of GM-CSF were found to be critical for function, residues 21-31 and residues 77-94. 8 Shanafelt and Kastelein examined structure-function relationship for murine GM-CSF by generating a series of small deletions scanning the length of the molecule? Four regions critical to activity were identified, residues 18-22, 34-41, 52-61, and 94-115. Similarly, Gough et a1 used mutagenesis of murine GM-CSF to show that residues 11-15,24-37,4749, and 81-89 are obligatory for function."
A problem common to all these approaches is that changes in primary structure may alter secondary or tertiary structure, and it is difficult, therefore, to distinguish critical structural regions from receptor-interaction sites. The use of antibodies as in the present study has certain advantages because they do not alter primary structure. Further, the epitopes recognized by antibodies are typically highly specific, and usually confined to only a few amino acids. However, antibody epitopes may be discontinuous with regards to primary amino acid sequence, and, thus, highly sensitive to protein folding. An MoAb apparently recognizing a discontinuous epitope of GM-CSF has been previously de~cribed?~ Antibodies can be particularly valuable in defining functional sites, because if an antibody neutralizes a biologic function, its epitope is likely to be within, or near, a critical site. Seven of the eight epitopes described here have been partially mapped using a combination of determining reactivity with synthetic peptides, reactivity with human/mouse hybrids, and cross-blocking studies. The four non-neutralizing epitopes were found to map to regions 1-16, 78-94, or 110-127. Neutralizing antibodies were found to map to regions 40-77, 78-94, or 110-127. Using mapping and cross-blocking studies, the "order" of the epitopes from N-terminus to C-terminus can also be estimated as NH,-However, several of these epitopes are likely to be complex. Antibodies 1089, 2114, and 2118 fail to react with reduced GM-CSF, and the reactivity of 1022, 3034, and 3092 is lessened for reduced GM-CSF. There are four cysteines in GM-CSF and previous studies have shown that the first and third form a disulfide bond (54-96) as do the second and fourth (88-121). In murine GM-CSF, Shanafelt and Kastelein have shown that the Cys-51 to Cys-93 disulfide bond is critical for function, while the second disulfide bond may not be.9 Each of the antibodies which react poorly with reduced GM-CSF have epitopes that map within or close to one of the two loops formed by these disulfide bonds. In contrast, antibody 4117, which maps to the N-terminus, binds equally well to reduced or non-reduced GM-CSF.
4117-1089~3092-2118/2114~1022-3034-
COOH.
The difficulty in more precisely identifying the epitopes of 1022 and 3034 may be ascribable to complex epitopes. The synthetic peptide studies suggest that the epitopes are in 110-127. However, both antibodies react with a humanmouse hybrid GM-CSF, hm 19, which contains only 20-94 residues as human. Thus, these epitopes may be discontinuous. However, our results do suggest that the region 110-127 may be functionally important. This finding is supported by the recent observation of Seelig et a1% that an anti-idiotype antibody raised against peptide 110-127 inhibits binding of lZI-GM-CSF to its receptor and inhibits proliferation. Thus, this segment of GM-CSF is likely to contain an important receptor-binding domain. This report describes the antibody mapping of nonfunctional epitopes of GM-CSF for the first time. Antibody 4117 has been shown to bind to the most N-terminal six to eight residues of mature GM-CSF. Thus, our results are in agreement with mutational and deletional studies that have indicated that this region is dispensible in terms of biologic function. This antibody may be useful for "labeling" GM-CSF even when it is bound to its receptor, because this epitope apparently remains exposed. The finding of nonneutralizing epitopes in small regions that also contain neutralizing epitopes, such as 78-94 (2114) or 110-127 (1022), is of interest, and demonstrates the fine specificity that is characteristic of MoAbs. More precise mapping of epitopes in these two critical areas is likely to be informative about which residues are of particular functional importance.
The epitopes of two neutralizing MoAbs have been previously characterized in detail using human/mouse hybrid GM-CSFS.'~ Antibody 221 epitope involves residues 83-94 and residue 23, while antibody 213 recognizes residues 78-83 plus other unidentified residues. In agreement with the partial epitope mapping, presented for the current series of antibodies, we found in preliminary experiments (Table 4, part B) that antibodies 3092 and 2118 effectively blocked binding of 213 to GM-CSF, while 2114 partially blocked binding, and 1089 and 3034 had no effect. Similarly, 3092 blocked binding of 221, while the other antibodies had minimal effects. Both 213 and 221 blocked binding of 3092 and partially blocked binding of each other, consistent with the partial overlap of their apparent epitopes. Thus, our results confirm that residues 78-94 are likely to be involved in the active site. Interestingly, the epitope of 2114 also may be in this area, but this antibody is not neutralizing and not blocking. This data suggests that there are silent areas in this region that will be interesting to further map.
The differences in the abilities of MoAbs 1089 and 2118 to neutralize biologic function as compared with block binding of GM-CSF to its receptor cannot be completely explained at this time. Antibody 1089 is one of the most potent neutralizing antibodies, but one of the least potent blocking antibodies. This result may simply be due to nonspecific binding of the antibody to the cell, possibly through Fc receptors, because the amount of nonspecific binding increases at high antibody concentration. The generation of F(ab)', antibody would be useful to further investigate this phenomenon, but has not yet been perFor personal use only. on October 24, 2017. by guest www.bloodjournal.org From formed. None of the other antibodies had any detectable nonspecific or Fc binding under the conditions used in this study (in the presence of human serum and 10 p,g/mL of irrelevant murine IgGl MoAb). The results obtained with antibody 2118 suggests that it is better at blocking than it is at neutralizing. The explanation for this, unless it is because of an artifact of the assay systems, will require additional studies.
It has not yet been determined how many GM-CSF receptors there are, nor whether the receptor expressed on mature myeloid cells such as neutrophils is identical to the receptor expressed on immature myeloid cells. In fact, we have evidence to suggest that there are two functional classes of high affinity GM-CSF ~eceptor.'~*~' Class I receptors are downregulated by GM-CSF itself or 12-0-tetradecanoy1phorbo1-13-acetate (TPA), and are typically expressed on neutrophils. Also, interleukin-3 (IL-3) does not compete with GM-CSF for binding to this class. Class I1 receptors are not down regulated by either GM-CSF or TF'A, IL-3 competes for GM-CSF binding, and this class is typically expressed by immature myeloid cells. Maturing myeloid cells and monocytes appear to express both classes of receptor. It has not yet been determined whether there is one binding protein, such as the placental GM-CSF binding protein recently described,*' or whether several exist. If a single binding protein exists, its functional characteristics may be modulated in different cells by associated proteins. Most of the neutralizing antibodies studied here blocked the activity of GM-CSF on both early and late myeloid cells, suggesting that most of the sites in GM-CSF that are critical for receptor binding and activation are the same in cells expressing both class I and class I1 receptors.
Overall, the data presented here confirm previous studies showing that widely separated areas of the molecule are important for function, further define those areas particularly in the C-terminus, define new areas which are dispensible, and suggest the possibility that binding of GM-CSF can be at least partially separated from receptor activation by one antibody (2118). The recent cloning of a low-affinity GM-CSF receptor has suggested that this receptor may be a member of a receptor family in which the receptors are characteristically composed of more than one polypeptide, such as the IL-2 and IL-6 receptors.z It is possible that there is another chain involved in the high-affinity GM-CSF receptor that may, or may not, also bind GM-CSF. In the case of the IL-2 receptor, both the c1 and the p chains bind ligand, while in the case of the IL-6 receptor, there are separate binding and signal-transducing proteins. If another GM-CSF binding protein is found, the antibodies described here will be of potential use in identifying the areas of GM-CSF that interact with this other receptor.
